Biopharmaceuticals Contract Manufacturing Market Updates

Global Biopharmaceuticals Contract Manufacturing Market size was valued at USD 16.5 billion in 2023 and is poised to grow from USD 17.85 billion in 2024 to USD 33.54 billion by 2032, growing at a CAGR of 8.2% during the forecast period (2025-2032).

Global biopharmaceuticals contract manufacturing market is consolidated in nature with the presence of several large market players operating across the globe. And, in terms of market share, top 5 players of the market are dominating the market including Boehringer Ingelheim, JSR Pharma, and Inno Biologics Sdn Bhd. These players are highly focusing on few business developing strategies including collaborations, mergers, new product innovations, and advance technology adoption to expand their geographical presence and product offerings. 'Lonza (Switzerland) ', 'Thermo Fisher Scientific Inc. (US) ', 'WuXi Biologics (China) ', 'Catalent, Inc. (US) ', 'Samsung Biologics (South Korea) ', 'Boehringer Ingelheim International GmbH (Germany) ', 'Fujifilm Holdings Corporation (Japan) ', 'AbbVie Inc. (US) ', 'Eurofins Scientific (Luxembourg) ', 'GenScript Biotech Corporation (China) ', 'AGC Inc. (Japan) ', 'Merck ', 'KGaA (Germany) ', 'JSR Corporation (Japan) ', 'Stelis (India) ', 'Recipharm AB (Sweden) ', 'Emergent (US) ', 'Shanghai Fosun Pharmaceutical Co., Ltd. (China) ', 'Lotte Biologics (South Korea) ', 'Hepalink Group (China) ', 'Curia Global, Inc. (US)'

Continuously rising generics demand, rising research & developments activities, and growing investments in advanced technologies are major factors expected to drive the growth of the global biopharmaceuticals market over the forecast period. Moreover, increasing demand for biological therapies and expansion in nuclear medicine sector coupled with the higher emphasis on specialty medicines are some others factors projected to have a positive impact on the global market over the coming years.

Introduction of AI Boosting Biopharmaceuticals Contract Manufacturing Market Growth: In the last few years, the biopharmaceutical contract manufacturing market has grown significantly owing to the growth in the scientific curiosity in various medical areas in which researchers have been searching and improving cure for fatal diseases. Additionally, increasing popularity of advanced artificial intelligence to analyze patient’s symptoms and help to track other people also with similar symptoms, is likely to create lucrative growth opportunities for the global market over the coming years.

Globally, North America region dominated the biopharmaceuticals contract manufacturing with a holding of strong market share in 2021 due to the large number of biomanufacturing facilities in the United States. Additionally, interventions & conferences conducted in the North America for pertinent developing technologies and major issues in applications of biologics for the better treatment of several chronic disorders are likely to fuel the adoption of contract manufacturing services in the region over the coming years.